NORTIVA
"NORTIVA" is a word mark owned by Nortiva Bio, Inc., filed at the USPTO on November 19, 2025. It is in its opposition period and covers classes 1, 5 and 42.
- Status
- Opposition period
- Since October 26, 2026
- Filed
- November 19, 2025
- Registered
- Not yet
- Expires
- Not recorded
- Application no.
- 99505425
- Registration no.
- Not yet
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 3 classes
Who owns NORTIVA
The owner and representative on file with the office.
Owner
Nortiva Bio, Inc.
Waltham, United States
Representative
Steven A. Abreu
Abreu Karol LLC
What the mark covers
The products and services NORTIVA is filed for, grouped by Nice class.
Excipients for use in the manufacture of pharmaceutical preparations; Chemical additives for use in the manufacture of pharmaceutical preparations; Active chemical ingredients for use in the manufacture of pharmaceuticals
Drug delivery agents in the form of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of long-acting, extended release, or continuous release capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations in the form of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations in the form of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations in the form of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings for the treatment of organ rejection, namely, immunosuppressants; pharmaceutical preparations in the form of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings for the treatment of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; antibiotics; pharmaceutical preparations used in organ transplantation; contraceptive preparations
Pharmaceutical research and development in the field of drug delivery; scientific research in the field of excipients and pharmaceutical formulation; medical research in the field of drug delivery; research and development of technology in the field of drug delivery; research and development of technology in the field of long-acting, extended release, or continuous release drug delivery agents; research and development of technology that facilitate the delivery of pharmaceutical preparations in the field of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings; pharmaceutical research in the field of drug delivery agents; pharmaceutical research in the field of capsules, pills, ingestible flexible stars, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; medical and scientific research in the field of drug delivery agents; medical and scientific research in the field of drug delivery for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical and scientific research in the field of drug delivery for antibiotics, and treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; medical and scientific research in the field of drug delivery for organ rejection and immunosuppressants; medical and scientific research in the field of drug delivery systems for the treatment of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; consulting services in the field of pharmaceutical research
What has happened so far
Steps recorded by the USPTO, newest first.
- Opposition instituted no. 999999
- Opposition papers received at ttab
- Official gazette publication confirmation e-mailed
- Published for opposition
- Notification of notice of publication e-mailed
- Approved for pub - principal register
- Teas/email correspondence entered
- Correspondence received in law office
- Teas response to office action received
- Teas change of correspondence received
10 earlier steps on the official record.
Oppositions and cancellations
Proceedings recorded against this mark by the USPTO. Reported as recorded, not legal advice.
About NORTIVA
Who owns the trademark "NORTIVA"?
The USPTO trademark "NORTIVA" (application 99505425) is owned by Nortiva Bio, Inc.
What is the status of "NORTIVA"?
Its status at the USPTO is: opposition period.
Get this data via the API
Everything on this page comes from the Signa API. Pull NORTIVA and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d2b61-bc30-7768-81f0-ac44aa2a1e64
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d2b61-bc30-7768-81f0-ac44aa2a1e64",
"object": "trademark",
"mark_text": "NORTIVA",
"status": {
"primary": "pending",
"stage": "pending_opposition"
},
"office_code": "US",
"application_number": "99505425",
"filing_date": "2025-11-19",
"nice_classes": [
1,
5,
42
],
"owners": [
{
"name": "Nortiva Bio, Inc.",
"entity_id": null
}
]
}